Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Importance Lipoprotein (a)(Lp [a]) is an important risk factor for atherothrombotic
cardiovascular disease and aortic stenosis, for which there are no treatments approved by …

Abstract Lipoprotein (a)[Lp (a)] is a well-recognized, independent risk factor for
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …

Abstract Aims Lipoprotein (a)[Lp (a)] is elevated in 20–30% of people. This study aimed to
assess the effect of statins on Lp (a) levels. Methods and results This subject-level meta …

Background High lipoprotein (a) concentrations present in 10%–20% of the population have
long been linked to increased risk of ischemic cardiovascular disease. It is unclear whether …

Evidence that elevated lipoprotein (a)(Lp [a]) levels contribute to cardiovascular disease
(CVD) and calcific aortic valve stenosis (CAVS) is substantial. Development of isoform …

Pathophysiological, epidemiological, and genetic studies provide strong evidence that
lipoprotein (a)[Lp (a)] is a causal mediator of cardiovascular disease (CVD) and calcific …

Calcific aortic stenosis (AS) is the most prevalent heart valve disorder in developed
countries. It is characterized by progressive fibro-calcific remodelling and thickening of the …

Summary Background Elevated lipoprotein (a)(Lp [a]) is a highly prevalent (around 20% of
people) genetic risk factor for cardiovascular disease and calcific aortic valve stenosis, but …